Landos Biopharma, Inc. is a clinical stage biopharmaceutical company based in Blacksburg, VA, dedicated to developing first-in-class, oral therapeutics for patients suffering from autoimmune diseases. With a strong focus on immunometabolic pathways, Landos has identified novel targets such as NLRX1 and PLXDC2, aiming to reprogram immune responses and enhance the treatment paradigm for conditions like ulcerative colitis and Crohn's disease.
Utilizing an advanced AI platform, Landos has built an innovative discovery platform that has generated multiple assets with unique mechanisms of action. With a portfolio of four clinical and preclinical assets, Landos is recognized as one of the most promising biotech companies in the field of immunology, striving to bring safer and more effective therapies to patients with chronic autoimmune diseases.
Generated from the website